Millipore Sigma Vibrant Logo

PP69 β-Amyloid Peptide (1-42), Human

β-Amyloid Peptide (1-42), Human: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

View Products on Sigmaaldrich.com
PP69
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
PP69-.25MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Frasco de vidrio .25 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      PP69-5MG
      Comprobando disponibilidad...
      —
      Disponibilidad a confirmar Disponibilidad a confirmar
      Ingrese cantidad 
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        El resto: se avisará
          El resto: se avisará
          Se avisará
          Póngase en contacto con el Servicio de Atención al Cliente
          Contact Customer Service

          		 Ampolla de plást. 5 mg
          Recuperando precio...
          No pudo obtenerse el precio
          La cantidad mínima tiene que ser múltiplo de
          Maximum Quantity is
          Al finalizar el pedido Más información
          Ahorró ()
           
          —
          Solicitar precio
          		 —
          Description
          OverviewWild-type, human Aβ1-42 peptide. This product is supplied in a form that is not neurotoxic prior to a pre-incubation step. The level of toxicity has been shown to correlate to the extent of β sheet structure.
          Catalogue NumberPP69
          Brand Family Calbiochem®
          SynonymsDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
          References
          ReferencesCitron, M., et al. 1997. Nature Med. 3, 67.
          Hardy, J. 1997. Trends in Neurosci. 20, 154.
          Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4109.
          Duff, K., et al. 1996. Nature 383, 710.
          Iwatsubo, T., et al. 1994. Neuron 13, 45.
          Suzuki, N., et al. 1994. Science 264, 133.
          Simmons, L.K., et al. 1994. Mol. Pharmacol. 45, 373.
          Product Information
          FormLyophilized
          FormulationSupplied as a chloride salt.
          Hill FormulaC₂₀₃H₃₁₂N₅₆O₅₉S
          Chemical formulaC₂₀₃H₃₁₂N₅₆O₅₉S
          Hygroscopic Hygroscopic
          PreservativeNone
          RegionSynthetic peptide corresponding to amino acid residues 1 - 42 of the processed human β-amyloid peptide.
          Quality LevelMQ100
          Applications
          Key Applications Substrate Cleavage Assay
          Application NotesSubstrate Cleavage Assays (30-100 μg/ml)
          Application Comments
          Biological Information
          ImmunogenHuman
          Purity≥95% by HPLC
          Physicochemical Information
          Peptide SequenceH-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsReconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications
          Global Trade Item Number
          Número de referencia GTIN
          PP69-.25MG 07790788059842
          PP69-5MG 04055977227062

          Documentation

          β-Amyloid Peptide (1-42), Human Ficha datos de seguridad (MSDS)

          Título

          Ficha técnica de seguridad del material (MSDS) 

          β-Amyloid Peptide (1-42), Human Certificados de análisis

          CargoNúmero de lote
          PP69

          Referencias bibliográficas

          Visión general referencias
          Citron, M., et al. 1997. Nature Med. 3, 67.
          Hardy, J. 1997. Trends in Neurosci. 20, 154.
          Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4109.
          Duff, K., et al. 1996. Nature 383, 710.
          Iwatsubo, T., et al. 1994. Neuron 13, 45.
          Suzuki, N., et al. 1994. Science 264, 133.
          Simmons, L.K., et al. 1994. Mol. Pharmacol. 45, 373.
          Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision26-October-2007 JSW
          SynonymsDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
          ApplicationSubstrate Cleavage Assays (30-100 μg/ml)
          DescriptionWild-type, human Aβ1-42 peptide. A number of mutations, identified in the gene encoding the β-amyloid precursor protein (βAPP), have been linked to early-onset Familial Alzheimer’s Disease. Mutations in the genes encoding presenilin 1 and presenilin 2 have also been shown to alter the processing of βAPP, resulting in increased extracellular concentration of β-amyloid peptide Aβ1-42(43) relative to Aβ1-40. Biophysical and biochemical experiments suggest that Aβ1-42(43) may serve as a catalyst for the aggregation and deposition of β-amyloid peptide (Aβ) leading to neurotoxic effects associated with senile plaque formation. Furthermore, antibodies recog-nizing Aβ1-42 revealed that the long form of the peptide is increased in presenilin and βAPP mutants, while other studies have used Aβ specific antibodies to prevent the in vitro fibrillar aggregation of Aβ. Amino acid sequence verified by amino acid analysis or sequencing. This product is supplied in a form that is not neurotoxic prior to a preincubation step. The appearance of toxicity has recently been shown to correlate to the extent of β sheet structure. Useful for neurotoxicity studies and substrate cleavage assays.
          Immunogen speciesHuman
          FormLyophilized
          FormulationSupplied as a chloride salt.
          Recommended reaction conditionsDissolve the lyophilized peptide at 1 mg/ml in 50 mM Tris-HCl, pH ≥9.0. Dilute peptide to an appropriate concentration with calcium, magnesium-free PBS and incubate at 37°C for 24-48 h prior to neurotoxicity studies. Suggested neurotoxic concentration is 30-100 µg/ml.
          Chemical formulaC₂₀₃H₃₁₂N₅₆O₅₉S
          Peptide SequenceH-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
          Purity≥95% by HPLC
          Solubility50 mM Tris•HCl, pH >9.0 (≤1 mg/ml)
          PreservativeNone
          Comments
          Storage -20°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsReconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.
          Toxicity Standard Handling
          ReferencesCitron, M., et al. 1997. Nature Med. 3, 67.
          Hardy, J. 1997. Trends in Neurosci. 20, 154.
          Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4109.
          Duff, K., et al. 1996. Nature 383, 710.
          Iwatsubo, T., et al. 1994. Neuron 13, 45.
          Suzuki, N., et al. 1994. Science 264, 133.
          Simmons, L.K., et al. 1994. Mol. Pharmacol. 45, 373.